The variability of sarcoidosis: Can we predict it?

Chest

Volumn 123, Issue 5, 2003, Pages 1329-1332

  Baughman, Robert P ^a,b   Lower, Elyse E ^a  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HLA ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY; VASCULOTROPIN;

CONTROLLED STUDY; DISEASE COURSE; EDITORIAL; ETHNIC GROUP; EYE DISEASE; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; GRANULOMA; HUMAN; MAJOR CLINICAL STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; PHENOTYPE; PRIORITY JOURNAL; RISK ASSESSMENT; SARCOIDOSIS; SKIN DISEASE;

EID: 0037541154     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.123.5.1329     Document Type: Editorial

References (24)

1. Pietinalho A, Ohmichi M, Hiraga Y, et al. The mode of presentation of sarcoidosis in Finland and Hokkaido, Japan: a comparative analysis of 571 Finnish and 686 Japanese patients. Sarcoidosis 1996; 13:159-166
2. Baughman RP, Teirstein AS, Judson MA, et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 2001; 164:1885-1889
3. Martinetti M, Tinelli C, Kolek V, et al. "The sarcoidosis map": a joint survey of clinical and immunogenetic findings in two European countries. Am J Respir Crit Care Med 1995; 152:557-564
4. Schurmann M, Lympany PA, Reichel P, et al. Familial sarcoidosis is linked to the major histocompatibility complex region. Am J Respir Crit Care Med 2000; 162:861-864
5. Martinetti M, Dugoujon JM, Tinelli C, et al. HLA-Gm/kappam interaction in sarcoidosis: suggestions for a complex genetic structure. Eur Respir J 2000; 16:74-80
6. Martinetti M, Luisetti M, Cuccia M. HLA and sarcoidosis: new pathogenetic insights. Sarcoidosis Vasc Diffuse Lung Dis 2002; 19:83-95
7. Furuya K, Yamaguchi E, Itoh A, et al. Deletion polymorphism in the angiotensin I converting enzyme (ACE) gene as a genetic risk factor for sarcoidosis. Thorax 1996; 51:777-780
8. Maliarik MJ, Rybicki BA, Malvitz E, et al. Angiotensin-converting engine gene polymorphism and risk of sarcoidosis. Am J Respir Crit Care Med 1998; 158:1566-1570
9. McGrath DS, Foley PJ, Petrek M, et al. Ace gene I/D polymorphism and sarcoidosis pulmonary disease severity. Am J Respir Crit Care Med 2001; 164:197-201
10. Schurmann M, Reichel P, Muller-Myhsok B, et al. Angioteninsin-converting enzyme (ACE) gene polymorphisms and familial occurrence of sarcoidosis. J Intern Med 2001; 249:77-83
11. Ziegenhagen MW, Benner UK, Zissel G, et al. Sarcoidosis: TNF-alpha release from alveolar macrophages and serum level of sIL-2R are prognostic markers. Am J Respir Crit Care Med 1997; 156:1586-1592
12. Baughman RP, Judson MA, Teirstein AS, et al. Thalidomide for chronic sarcoidosis. Chest 2002; 122:227-232
13. Baughman RP, Lower EE. Infliximab for refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2001; 18:70-74
14. Seitzer U, Swider C, Stuber F, et al. Tumour necrosis factor alpha promoter gene polymorphism in sarcoidosis. Cytokine 1997; 9:787-790
15. Takashige N, Naruse TK, Matsumori A, et al. Genetic polymorphisms at the tumour necrosis factor loci (TNFA and TNFB) in cardiac sarcoidosis. Tissue Antigens 1999; 54:191-193
16. Spies T, Morton CC, Nedospasov SA, et al. Genes for the tumor necrosis factors alpha and beta are linked to the human major histocompatibility complex. Proc Natl Acad Sci U S A 1986; 83:8699-8702
17. Renner W, Kotschan S, Hoffmann C, et al. A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J Vasc Res 2000; 37:443-448
18. Koyama S, Sato E, Haniuda M, et al. Decreased level of vascular endothelial growth factor in bronchoalveolar lavage fluid of normal smokers and patients with pulmonary fibrosis. Am J Respir Crit Care Med 2002; 166:382-385
19. Bresnitz EA, Stolley PD, Israel HL, et al. Possible risk factors for sarcoidosis: a case-control study. Ann N Y Acad Sci 1986; 465:632-642
20. Hance AJ, Basset F, Saumon G, et al. Smoking and interstitial lung disease: the effect of cigarette smoking on the incidence of pulmonary histiocytosis X and sarcoidosis. Ann N Y Acad Sci 1986; 465:643-656
21. Judson MA, Baughman RP, Teirstein AS, et al. Defining organ involvement in sarcoidesis: the ACCESS proposed instrument. Sarcoidosis Vasc Diffuse Lung Dis 1999; 16:75-86
22. Neville E, Walker AN, James DG. Prognostic factors predicting the outcome of sarcoidosis: an analysis of 818 patients. Q J Med 1983; 208:525-533
23. Sato H, Grutters JC, Pantelidis P, et al. HLA-DQB1*0201: a marker for good prognosis in British and Dutch patients with sarcoidosis. Am J Respir Cell Mol Biol 2002; 27:406-412
24. Pietinalho A, Furuya K, Yamaguchi E, et al. The angiotensin-converting enzyme DD gene is associated with poor prognosis in Finnish sarcoidosis patients. Eur Respir J 1999; 13:723-726